HB-EGF Inhibitors
Common HB-EGF Inhibitors include, but are not limited to Diphtheria Toxin, CRM Mutant CAS 92092-36-9, Gefitinib CAS 184475-35-2, Lapatinib CAS 231277-92-2, Erlotinib, Free Base CAS 183321-74-6 and U-0126 CAS 109511-58-2.
Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a crucial member of the epidermal growth factor (EGF) family, exerting profound effects on diverse cellular processes. Central to its functionality is its involvement in the regulation of fundamental cellular activities, including cell growth, proliferation, differentiation, and migration. The intricate orchestration of these processes is essential for maintaining tissue homeostasis and responding to physiological demands. In particular, HB-EGF plays a pivotal role in wound healing, where it facilitates the repair of damaged tissues by promoting cell migration and proliferation. Additionally, it contributes to tissue regeneration, ensuring the restoration of normal cellular function after injury.
The inhibition of HB-EGF emerges as a critical strategy in unraveling its complex functions and dissecting its involvement in diseases. HB-EGF inhibitors serve as precise molecular tools to manipulate the activity of this growth factor, allowing researchers to discern the specific contributions of HB-EGF in both normal and pathological conditions. By selectively blocking HB-EGF, scientists can investigate the downstream signaling cascades initiated by this growth factor, shedding light on the molecular events that drive cellular processes. Furthermore, the use of HB-EGF inhibitors enables the exploration of research, as understanding the role of HB-EGF in cellular processes opens avenues for targeted strategies to mitigate its pathological effects.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Diphtheria Toxin, CRM Mutant | 92092-36-9 | sc-203924 | 0.25 mg | $639.00 | 1 | |
Diphtheria Toxin, CRM Mutant is a mutant form of diphtheria toxin that binds to HB-EGF, preventing its interaction with its receptor and inhibiting cell growth signaling. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR inhibitor that could indirectly impact HB-EGF signaling by targeting the receptor through which HB-EGF exerts its effects. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is a dual EGFR/HER2 inhibitor that might indirectly affect HB-EGF signaling by targeting receptors involved in its downstream signaling pathways. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib, an EGFR inhibitor, could indirectly influence HB-EGF signaling by targeting EGFR, which is involved in the activation of HB-EGF-mediated pathways. | ||||||
PD 153035 | 153436-54-5 | sc-205909 | 5 mg | $146.00 | 5 | |
PD 153035 is a reversible EGFR inhibitor that could indirectly affect HB-EGF signaling by targeting EGFR, which is involved in HB-EGF-mediated pathways. | ||||||
TAPI-1 | 171235-71-5 | sc-222337 | 1 mg | $656.00 | 15 | |
TAPI-1 is a metalloproteinase inhibitor that may indirectly inhibit HB-EGF cleavage from the cell surface, reducing the availability of soluble HB-EGF. | ||||||
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $165.00 $214.00 $396.00 $617.00 $4804.00 | 19 | |
Marimastat is a broad-spectrum matrix metalloproteinase inhibitor that might indirectly inhibit HB-EGF cleavage, affecting its release and downstream signaling. | ||||||
Batimastat | 130370-60-4 | sc-203833 sc-203833A | 1 mg 10 mg | $175.00 $370.00 | 24 | |
Batimastat is a synthetic matrix metalloproteinase inhibitor that could indirectly impact HB-EGF cleavage and release, affecting downstream signaling. | ||||||